Van Tuyl Christopher 4
4 · Immunovant, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) CLO Christopher Van Tuyl Sells Shares After Option Exercise
What Happened Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), exercised 17,824 stock options on June 26, 2026 at an exercise price of $15.20 per share (cost $270,925) and sold the resulting 17,824 shares the same day in two open-market transactions for aggregate proceeds of about $682,887. The transactions show total gross proceeds from the sales of $682,887 and an exercise cost of $270,925 (approximate net before taxes/fees of $411,962).
Key Details
- Transaction date: June 26, 2026.
- Option exercise: 17,824 shares exercised at $15.20 each (total reported cost $270,925).
- Open-market sales: 14,982 shares at a weighted avg $38.19 (proceeds $572,163) and 2,842 shares at a weighted avg $38.96 (proceeds $110,724). Footnotes report sale price ranges of $37.75–$38.70 and $38.82–$39.15 for the respective groups.
- Derivative disposition line: the option/derivative was converted/terminated upon exercise (reported as disposed at $0).
- Shares owned after the transactions: not specified in the information provided.
- Filing timeliness: report period and filing date are both June 26, 2026 — no late filing indicated in the provided data.
- Relevant footnote: the options granted had an April 1, 2025 grant date and vest 25% on April 1, 2026 with the remainder vesting monthly over the following three years.
Context This was an option exercise immediately followed by sales of the exercised shares (a same-day exercise-and-sell pattern often used to cover exercise cost and tax obligations). The filing is factual and does not disclose motivation. Purchases are generally more informative about insider sentiment; this report documents a routine exercise and sale.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-06-26$15.20/sh+17,824$270,925→ 198,421 total - Sale
Common Stock
[F1]2026-06-26$38.19/sh−14,982$572,163→ 183,439 total - Sale
Common Stock
[F2]2026-06-26$38.96/sh−2,842$110,724→ 180,597 total - Exercise/Conversion
Stock Option (right to buy)
[F3]2026-06-26−17,824→ 53,707 totalExercise: $15.20Exp: 2035-04-01→ Common Stock (17,824 underlying)
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date.